Here are the 424B prospectus supplements from Nasus Pharma Ltd. (NSRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NSRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NSRX filings page.
Nasus Pharma Ltd (NSRX) is launching a primary at-the-market offering of up to $8,500,000 of ordinary shares under its Form F-3 shelf, using BTIG, LLC as sales agent. Sales, if any, will be made from time to time into the market at prevailing prices, and Nasus is not obligated to sell any shares.
BTIG will use commercially reasonable efforts to place shares and will receive up to 3% of gross proceeds as commission, with each sale treated as an underwritten transaction. Based on an illustrative price of $3.65 per share, selling 2,328,767 shares would increase shares outstanding from 11,710,808 to up to 14,042,575, creating an immediate dilution of $2.29 per share for new investors and a $0.42 per-share accretion in net tangible book value for existing holders.
Nasus plans to use net proceeds primarily for ongoing clinical development of its lead intranasal epinephrine candidate NS002 for anaphylaxis, to start clinical studies for additional pipeline products such as NS003, NS004 and NS005, and for working capital and general corporate purposes. The company highlights significant risks, including recurring losses, substantial additional capital needs, potential going concern issues, limited trading liquidity, and the possibility of further dilution from future equity financings or option and warrant exercises.